InsidersTradesSigma
DiaMedica Therapeutics Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the DiaMedica Therapeutics Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, DiaMedica Therapeutics Inc. has logged 59 insider filings. Market capitalisation: €413.3m. The latest transaction was reported on 4 June 2026 (50 - Grant of options). Among the most active insiders: Giuffre Randall Michael. The full history is openly available.
59
Insider Decl.
0
Thresholds
€28m
28 ops.
Buy Volume
€3m
1 ops.
Sell Volume
29Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 4 June 2026
Declarations59 total
67,500 sharesOptionsTSXSEDI:4728899
162,000 sharesOptionsTSXSEDI:4728894
40,412 sharesOptionsTSXSEDI:4728882
40,412 sharesOptionsTSXSEDI:4728872
40,412 sharesOptionsTSXSEDI:4728863
40,412 sharesOptionsTSXSEDI:4728857
40,412 sharesOptionsTSXSEDI:4728855
51,189 sharesOptionsTSXSEDI:4728850
380,000 sharesOptionsTSXSEDI:4728846
12,000 shares@ US$2.2010.8% of flowCommon StockSEC:0001759855-25-000006:0
293,601 shares@ US$5.909116.7% of flowCommon SharesSEC:0001104659-25-087410:0
Ideal exit: 10 May 2026 (T+270)
400,000 shares@ US$3.50100.0% of flowVoting Common Shares, no par value per shareSEC:0001437749-25-023532:0
Ideal exit: 19 Apr 2026 (T+270)
1,542,857 shares@ US$3.5062.1% of flowCommon SharesSEC:0001104659-25-070920:0
Ideal exit: 19 Apr 2026 (T+270)
2,857,142 shares@ US$3.5043.6% of flowCommon SharesSEC:0001104659-25-070900:0
Ideal exit: 19 Apr 2026 (T+270)
24,000 shares@ US$2.117.7% of flowVoting Common Shares, no par value per shareSEC:0001760016-25-000004:0
12,000 shares@ US$2.114.4% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000009:0
5,290 shares@ US$5.3422.5% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000001:0
10,393 shares@ US$5.348.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000002:0
10,861 shares@ US$5.3410.1% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000004:0
9,925 shares@ US$5.3458.6% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000003:0
15,917 shares@ US$5.3433.9% of flowVoting Common Shares, no par value per shareSEC:0001235802-25-000005:0
1,200,000 shares@ US$2.5025.5% of flowCommon SharesSEC:0001104659-24-076844:0
Ideal exit: 25 Mar 2025 (T+270)
1,200,000 shares@ US$2.50100.0% of flowCommon SharesSEC:0001104659-24-076840:0
Ideal exit: 25 Mar 2025 (T+270)
21,428 shares@ US$2.8022.5% of flowVoting Common Shares, no par value per shareSEC:0001235802-24-000002:0
19,196 shares@ US$2.808.7% of flowVoting Common Shares, no par value per shareSEC:0001235802-24-000001:0
25 of 59 declarations
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on the Nasdaq Stock Market LLC under the ticker DMAC in the United States. For French-, Belgian- and Swiss-based investors, it is best understood as a development-stage biotech with a concentrated asset profile rather than a diversified commercial pharmaceutical company. The company’s strategy is focused on vascular diseases driven by impaired blood flow and endothelial dysfunction, with current clinical emphasis on preeclampsia, fetal growth restriction, and acute ischemic stroke. ([diamedica.com](https://www.diamedica.com/investors)) DiaMedica has a longer corporate history than its present market profile might suggest. The business traces back to 2000, and its current identity was shaped through corporate restructuring and a name change in 2016. Its headquarters are in Minneapolis, Minnesota, placing it in a well-established U.S. life-sciences hub. In market terms, DMAC remains a small-cap clinical biotech whose valuation case is tied to pipeline execution, clinical readouts, and continued access to capital markets to fund development. ([diamedica.com](https://www.diamedica.com/investors/financial-reports/sec-filings/content/0001437749-25-009703/0001437749-25-009703.pdf)) The company’s lead program is DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1). DiaMedica describes DM199 as the first pharmaceutically active recombinant version of KLK1, designed to restore vascular function and improve blood flow while potentially reducing inflammation and oxidative stress. In preeclampsia and fetal growth restriction, the goal is to address the underlying pathophysiology rather than only symptoms. In acute ischemic stroke, the rationale is to enhance collateral perfusion and potentially broaden the treatment opportunity relative to current care pathways. ([diamedica.com](https://www.diamedica.com/company?utm_source=openai)) From a competitive standpoint, DiaMedica operates in a specialized but crowded biotech landscape. Its differentiation comes from the KLK1 biology and from the fact that kallikrein-based therapeutic concepts have historical precedent in Asia for vascular indications. That said, the company does not yet have a commercial product portfolio, so the investment thesis is highly binary and depends primarily on the quality of clinical evidence, enrollment progress, and regulatory traction. As with many clinical-stage names, the principal risks remain trial success, financing needs, and dilution. ([diamedica.com](https://www.diamedica.com/investors/press-releases/detail/1723/diamedica-therapeutics-reports-full-year-2025-financial)) Recent company updates reinforce that clinical development remains the central value driver. In 2025 DiaMedica disclosed interim Phase 2 preeclampsia results, and in 2026 it has continued to publish business updates and financial results, including commentary that the ReMEDy2 trial is continuing to enroll and expand globally. The company has also been active on the conference circuit in 2026, which is consistent with a small-cap biotech seeking broader institutional awareness. For investors monitoring SEC Form 4 insider transactions, DMAC should therefore be viewed as a research-driven Nasdaq issuer in the United States where insider activity, clinical milestones, and trial data can all have material impact on sentiment. ([diamedica.com](https://www.diamedica.com/))
